Therapeutic protein-polymer conjugates: advancing beyond PEGylation

Area of Science:

• Bioconjugation chemistry
• Pharmaceutical sciences
• Drug delivery systems

Background:

• Protein-polymer conjugates, particularly poly(ethylene glycol) (PEG) conjugates, are vital FDA-approved therapeutics.
• PEGylation enhances drug half-life, reducing dosing frequency and improving patient compliance.
• Limitations of PEG necessitate the development of alternative polymer technologies.

Purpose of the Study:

• To review current protein-PEG conjugates in therapeutic use.
• To summarize alternative polymer technologies for protein therapeutics.
• To suggest future research directions in protein conjugation.

Main Methods:

• Review of established methods for protein-PEG conjugate production.
• Exploration of novel approaches using controlled radical polymerization for alternative conjugates.
• Analysis of pharmacokinetic properties and stability of protein-polymer systems.

Main Results:

• Protein-PEG conjugates are a cornerstone of modern therapeutics due to extended circulation times.
• Alternative polymers are emerging with potential for enhanced stability and biodegradability.
• Controlled radical polymerization offers precise control over polymer architecture for conjugation.

Conclusions:

• Advancements in polymer science are crucial for developing next-generation protein therapeutics.
• Alternative polymers to PEG hold promise for overcoming current limitations and expanding therapeutic applications.
• Future research should focus on novel conjugation strategies and materials for improved protein drug delivery.